| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qiu-Xian Chen, Yong-Bin Zhang, Wei-Ming Zeng, Yi-Chen Cai, Chen-Bin Lv, Ming-Qiao Lian, Rong-Jie Huang, Ming-Jie Lian, Wei-Long Lian, Qian-Hui Xu, Yu-Qin Sun and Li-Sheng Cai |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Wu Jieping Medical Fund |
No. 320.6750.2022-09-14 |
| The climbing Fund of PhD workstation, Zhangzhou Affiliated Hospital of Fujian Medical University |
No. PDB202412 |
|
| Corresponding Author |
Li-Sheng Cai, Chief Physician, Department of General Surgery, Zhangzhou Affiliated Hospital of Fujian Medical University, No. 59 West Shengli Road, Zhangzhou 363000, Fujian Province, China. wxccls2024@163.com |
| Key Words |
Gastric cancer; Neoadjuvant therapy; Immune checkpoint inhibitor; Efficacy; Safety |
| Core Tip |
This study investigated sintilimab (an immune checkpoint inhibitor) plus nab-paclitaxel and S-1 as neoadjuvant therapy for locally advanced gastric cancer. The combination significantly improved pathological complete response and major pathological response rates, while also demonstrating superior 2-year disease-free survival compared to chemotherapy alone, without additional safety concerns. These findings support its potential as an effective preoperative treatment strategy for locally advanced gastric cancer. |
| Publish Date |
2025-05-30 10:57 |
| Citation |
<p>Chen QX, Zhang YB, Zeng WM, Cai YC, Lv CB, Lian MQ, Huang RJ, Lian MJ, Lian WL, Xu QH, Sun YQ, Cai LS. Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer. <i>World J Gastrointest Surg</i> 2025; 17(6): 106361</p> |
| URL |
https://www.wjgnet.com/1948-9366/full/v17/i6/106361.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v17.i6.106361 |
